IDEAYA Biosciences, Inc. (IDYA)
- Previous Close
38.62 - Open
38.90 - Bid 28.18 x 200
- Ask 39.09 x 100
- Day's Range
38.17 - 39.60 - 52 Week Range
18.11 - 47.74 - Volume
116,867 - Avg. Volume
710,512 - Market Cap (intraday)
2.914B - Beta (5Y Monthly) 0.80
- PE Ratio (TTM)
-- - EPS (TTM)
-1.96 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
53.00
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
www.ideayabio.comRecent News: IDYA
Performance Overview: IDYA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IDYA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IDYA
Valuation Measures
Market Cap
2.89B
Enterprise Value
2.37B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
94.99
Price/Book (mrq)
4.65
Enterprise Value/Revenue
101.14
Enterprise Value/EBITDA
-18.13
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-16.20%
Return on Equity (ttm)
-23.28%
Revenue (ttm)
23.39M
Net Income Avi to Common (ttm)
-112.96M
Diluted EPS (ttm)
-1.96
Balance Sheet and Cash Flow
Total Cash (mrq)
525.11M
Total Debt/Equity (mrq)
0.46%
Levered Free Cash Flow (ttm)
-70.28M